スズキ　アツシ   Suzuki Atsushi   鈴木　敦    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
言語種別	英語
発表タイトル	Pharmacologic management of arrhythmia in heart failure
会議名	The 21st Annual Scientific Meeting of the Japanese Heart Failure Society
主催者	Japanese Heart Failure Society
学会区分	全国規模の学会
発表形式	口頭
講演区分	シンポジウム・ワークショップ パネル（指名）
発表者・共同発表者	◎SHIGA Tsuyoshi, SUZUKI Atsushi, SHODA Morio, HAGIWARA Nobuhisa
発表年月日	2017/10/12
開催地 （都市, 国名）	Akita, JAPAN
学会抄録	Journal of Cardiac Failure 23(10),S8 2017
概要	Arrhythmia confers a substantial risk of mortality and morbidity in patients with heart failure (HF). The treatment goals of arrhythmia in HF patients are to improve prognosis and quality of life. Sudden cardiac death (SCD), which is primarily caused by ventricular tachycardia (VT)/fibrillation (VF), accounts for approximately onethird of all deaths in HF patients. Implantable cardioverter-defibrillator (ICD) is useful for preventing SCD, but the improvement of outcome is limited in patients with advanced HF. Beta-blockers reduces SCD and improves survival. Amiodarone is potentially effective to prevent VT/VF. Intravenous nifekalant, a pure class III antiarrhythmic drug, or intravenous amiodarone is useful in the emergency treatment of VT/VF. Recently, short-acting intravenous beta-blocker such as landiolol can be tried. Atrial fibrillation (AF) frequently occurs in HF patients and leads to clinical and hemodynamic deterioration. They also increase a risk of HF deterioration. Amiodarone is safely used in HF patients. In AF patients with congestive, landiolol can also be used to control the ventricular rate as an intravenous infusion. In conclusions, standard pharmacologic therapy for HF including beta-blockers should be optimized to prevent arrhythmia as well as mortality. In emergency and acute care settings, short-acting beta-blocker may have an important role in management of arrhythmia and HF.